Abstract: The present disclosure provides methods for detecting a high-risk phenotype of a mast cell tumor (MCT) in a biological sample from a mammal, preferably a dog. Kits, PCR probes and primers to detect high-risk MCT are also provided.

Abstract: This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.

Abstract: This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.

Abstract: The present disclosure provides systems and methods for managing blood glucose in a subject. An insulin delivery cannula may comprise a hollow tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of a concentrated insulin or insulin analog formulation of at least about 150 units per milliliter. The distal end may be configured to deliver the concentrated insulin or insulin analog formulation into a subcutaneous space. A continuous amperometric or coulometric glucose sensor may located no more than a pre-determined distance away from the distal end. An insulin pump may be fluidically coupled to the proximal end, and may be attached to the insulin delivery cannula directly or via an intervening tube. The glucose sensor and the insulin delivery cannula may be configured to be inserted into the subcutaneous space simultaneously by a single insertion device.

Abstract: The present disclosure provides methods for detecting a high-risk phenotype of a mast cell tumor (MCT) in a biological sample from a mammal, preferably a dog. Kits, PCR probes and primers to detect high-risk MCT are also provided.

Abstract: The present disclosure provides methods for detecting a high-risk phenotype of a mast cell tumor (MCT) in a biological sample from a mammal, preferably a dog. Kits, PCR probes and primers to detect high-risk MCT are also provided.

Abstract: This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.

Abstract: This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.

Abstract: This invention is directed to a method of diagnosing bladder cancer in dogs.

Abstract: This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.

Abstract: This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.

Abstract: This invention is directed to a method of diagnosing bladder cancer in dogs.

Abstract: The present disclosure provides methods for detecting a high-risk phenotype of a mast cell tumor (MCT) in a biological sample from a mammal, preferably a dog. Kits, PCR probes and primers to detect high-risk MCT are also provided.

Abstract: Methods for predicting a disease free time interval (DFI) for a cancer patient under consideration for initial or further chemotherapy treatment are disclosed. The methods include obtaining a biological sample from a patient and detecting a copy number of chromosome region A1 and/or C2. The mean copy number per cell is correlated with a DFI for the subject. The chemotherapy can include doxorubicin and/or L-asparaginase treatment. Also provided are kits for predicting DFI in a subject with cancer and computer readable storage media for performing the presently disclosed methods.

Abstract: This disclosure is directed to the discovery of an improved method to diagnose malignant melanoma of the oral cavity in the dog.

Abstract: This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.

Abstract: This invention is directed to a method of diagnosing bladder cancer in dogs.

Abstract: Methods for predicting a disease free time interval (DFI) for a cancer patient under consideration for initial or further chemotherapy treatment are disclosed. The methods include obtaining a biological sample from a patient and detecting a copy number of chromosome region A1 and/or C2. The mean copy number per cell is correlated with a DFI for the subject. The chemotherapy can include doxorubicin and/or L-asparaginase treatment. Also provided are kits for predicting DFI in a subject with cancer and computer readable storage media for performing the presently disclosed methods.

Abstract: The invention provides methods and compositions for identifying subjects, including canine subjects, having an elevated risk of developing cancer or having an undiagnosed cancer. These subjects are identified based on the presence of germ-line allele(s) and markers and various somatic mutations.

Abstract: Methods for predicting a disease free time interval (DFI) for a cancer patient under consideration for initial or further chemotherapy treatment are disclosed. The methods include obtaining a biological sample from a patient and detecting a copy number of chromosome region A1 and/or C2. The mean copy number per cell is correlated with a DFI for the subject. The chemotherapy can include doxorubicin and/or L-asparaginase treatment. Also provided are kits for predicting DFI in a subject with cancer and computer readable storage media for performing the presently disclosed methods.